Table 5.
Serum Thyroglobulin and Thyrotropin Levels in Six Patients Who Received Vemurafenib Plus CDX-3379
| Patient no. | Tg at baseline (TSH) | Tg on W6D1 V+C (TSH) | Tg at ∼5 weeks post-tx with 131I (TSH) | Tg at ∼3 months post-tx with 131I (TSH) | Tg at ∼6 months post-tx with 131I (TSH) |
|---|---|---|---|---|---|
| 131I treated | |||||
| 1 | 18.7 (2.30) | 22.9 (6.22) | 75.6 (17.89) | 19.8 (0.87) | 11.3 (0.02) |
| 2 | 101.3 (0.25) | 79.1 (1.56) | 118.4 (0.47) | 132.3 (0.4) | NA |
| 4 | 196.8 (0.88) | 11.5 (0.53) | 25.8 (5.44) | 6.7 (2.40) | 3.7 (0.05) |
| 5 | 0.2 (0.14) | 0.1 (3.48) | 0.1 (0.26) | <0.1 (0.19) | NA |
| No 131I given | |||||
| 3 | 549.0 (0.02) | 176.3 (0.19) | NA | NA | 323.8 (0.02)b |
| 7 | <0.1* (0.09) | <0.1* (0.40) | NA | <0.1* (3.87)c | NA |
a
Levels of serum Tg (TSH) are expressed as the following units: ng/mL (mIU/mL).
b
Checked ∼7 months after study.
c
Checked ∼3 months after study.
*
Patient 7 Tg was undetectable owing to the presence of thyroglobulin antibodies.
NA, not available; post-tx, post-treatment; Tg, thyroglobulin; TSH, thyrotropin; V+C, vemurafenib plus CDX-3379; W6D1, week 6 day 1.